Agilent just downgraded at BofA, here’s why

BofA analyst Derik de Bruin downgraded Agilent to Neutral from Buy with a price target of $133, up from $130. Shares are up about 13% since the company reported Q4 results on November 20, and valuation appears full, the analyst tells investors in a research note. The firm thinks additional upside is likely limited given the lack of visibility across the life sciences tools market.